Fig. 2: Baseline biomarkers of collagen crosslinking (LOXL2), collagen formation (Pro-C3), and collagen degradation (C1M and C6M) in the exploratory cohort. | npj Breast Cancer

Fig. 2: Baseline biomarkers of collagen crosslinking (LOXL2), collagen formation (Pro-C3), and collagen degradation (C1M and C6M) in the exploratory cohort.

From: Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer

Fig. 2: Baseline biomarkers of collagen crosslinking (LOXL2), collagen formation (Pro-C3), and collagen degradation (C1M and C6M) in the exploratory cohort.The alternative text for this image may have been generated using AI.

Tukey boxplots (lines representing 25th, 50th, and 75th percentile with whiskers representing lowest and highest values and *representing outliers defined as 1.5× the 75th or 25th percentile respectively) of LOXL2, C1M, Pro-C3, and C6M levels in those with metastatic (M) and adjuvant (A) disease compared with healthy controls (H). Groups were compared using a Kruskal–Wallis test. Levels of all collagen biomarkers were higher in those with disease, metastatic and adjuvant, as compared with healthy controls. p-Values: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.

Back to article page